Okay, let's tackle this question. The patient had a total thyroidectomy for a thyroid mass. The surgeon noticed enlarged parathyroid glands. The histology shows neuroendocrine-type cells and amyloid. The question is about the oncogene involved here.

First, the core concept here is likely a syndrome that affects both the thyroid and parathyroid glands. The presence of neuroendocrine cells and amyloid in the thyroid makes me think of medullary thyroid carcinoma (MTC). MTC is part of Multiple Endocrine Neoplasia type 2 (MEN2), which also includes parathyroid hyperplasia or adenomas leading to hyperparathyroidism. So the oncogene associated with MEN2 would be the RET proto-oncogene.

Now, the options aren't provided, but common oncogenes related to endocrine tumors include RET, RAS, p53, and others. For example, MEN2 is caused by mutations in RET. The amyloid in MTC comes from calcitonin, so that's a key point. The parathyroid involvement in MEN2 would be due to hyperplasia, leading to hypercalcemia.

The wrong options might include other oncogenes like RAS (common in other cancers), p53 (Li-Fraumeni syndrome), or BRCA (breast/ovarian). Each of these is associated with different syndromes and not MEN2.

The clinical pearl here is to remember that MEN2 involves the thyroid (MTC), parathyroid (hyperplasia), and adrenal medulla (pheochromocytoma), all linked to RET mutations. So the correct answer is the RET oncogene.

**Core Concept**
This question evaluates the association between medullary thyroid carcinoma (MTC) and parathyroid hyperplasia in Multiple Endocrine Neoplasia Type 2 (MEN2), focusing on the genetic basis of these tumors. The key is recognizing that neuroendocrine differentiation and amyloid deposition in the thyroid are hallmarks of MTC, while parathyroid involvement is a defining feature of MEN2.

**Why the Correct Answer is Right**
The **RET proto-oncogene** is mutated in MEN2, leading to MTC (thyroid) and parathyroid hyperplasia/adenomas. RET is a receptor tyrosine kinase that, when mutated, causes constitutive activation of signaling pathways like MAPK/ERK, driving tumor formation. Amyloid in MTC results from calcitonin secretion by neuroendocrine C-cells. Parathyroid hyperplasia in MEN2 is due to parathyroid gland overactivity, not hyperplasia itself, but the syndrome links both glands via RET mutations.

**Why Each Wrong Option is Incorrect**
**Option A:** *RAS* mutations are associated with sporadic MTC or other cancers (e.g., pancreatic, colorectal), but not MEN2.
**Option B:** *p53* mutations cause Li-Fraumeni syndrome, characterized by early-onset sarcomas, breast cancer, and brain tumors.
**Option C:** *BRCA1/2* mutations are linked to hereditary breast and ovarian cancer, not endocrine tumors.
**Option D:** *MYC* amplification is seen in neuroblastomas and some leukemias, unrelated

✓ Correct Answer: D. ret